| Literature DB >> 24265736 |
Toshiaki Ohkuma1, Hiroki Fujii, Masanori Iwase, Shinako Ogata-Kaizu, Hitoshi Ide, Yohei Kikuchi, Yasuhiro Idewaki, Tamaki Jodai, Yoichiro Hirakawa, Udai Nakamura, Takanari Kitazono.
Abstract
OBJECTIVE: Few studies have so far investigated the impact of sleep duration on chronic kidney disease in diabetic patients. The objective of the present study was to examine the relationship between sleep duration and albuminuria in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: A total of 4,870 Japanese type 2 diabetic patients ≥20 years of age were divided into six groups according to self-reported sleep duration: less than 4.5 hours, 4.5-5.4 hours, 5.5-6.4 hours, 6.5-7.4 hours, 7.5-8.4 hours and more than 8.5 hours. The association between sleep duration and urinary albumin-creatinine ratio (UACR) was examined cross-sectionally.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24265736 PMCID: PMC3827127 DOI: 10.1371/journal.pone.0078968
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of the study subjects according to sleep duration.
| Sleep duration (h) | |||||||
| <4.5 | 4.5–5.4 | 5.5–6.4 | 6.5–7.4 | 7.5–8.4 | ≥8.5 | P value | |
| n | 163 | 530 | 1228 | 1342 | 1141 | 466 | |
| Age (years) | 63±11 | 64±11 | 64±10 | 65±10 | 68±9 | 70±9 | <0.001 |
| Male (%) | 44 | 49 | 55 | 57 | 61 | 67 | <0.001 |
| Duration of diabetes (years) | 15±10 | 15±11 | 15±10 | 15±10 | 17±11 | 18±11 | <0.001 |
| Smoking habits | <0.001 | ||||||
| Current smoker (%) | 24 | 17 | 20 | 18 | 17 | 19 | |
| Former smoker (%) | 21 | 30 | 31 | 33 | 38 | 40 | |
| Never smoker (%) | 55 | 54 | 49 | 49 | 45 | 41 | |
| Current drinker (%) | 29 | 39 | 41 | 39 | 39 | 40 | 0.10 |
| Regular exercise (%) | 59 | 65 | 67 | 73 | 73 | 70 | <0.001 |
| Total energy intake (kcal/day) | 1639±541 | 1631±518 | 1683±470 | 1705±502 | 1696±485 | 1716±517 | 0.03 |
| Total protein intake (g/day) | 65±25 | 65±26 | 67±23 | 68±24 | 68±24 | 69±26 | 0.12 |
| Depressive symptoms (%) | 26 | 13 | 7 | 7 | 8 | 9 | <0.001 |
| Hypnotic use (%) | 25 | 12 | 12 | 10 | 11 | 10 | <0.001 |
| BMI (kg/m2) | 25.3±4.4 | 24.8±4.5 | 23.9±3.8 | 23.6±3.8 | 23.4±3.4 | 23.4±3.5 | <0.001 |
| Obesity (%) | 15 | 8 | 6 | 5 | 4 | 5 | <0.001 |
| HbA1c (%) | 7.71±1.18 | 7.52±1.11 | 7.44±1.02 | 7.39±1.04 | 7.40±1.01 | 7.46±1.07 | 0.002 |
| OHA use (%) | 70 | 65 | 65 | 63 | 64 | 61 | 0.30 |
| Insulin use (%) | 26 | 27 | 26 | 28 | 29 | 34 | 0.05 |
| Systolic blood pressure (mmHg) | 130±16 | 132±17 | 130±17 | 130±16 | 131±18 | 132±18 | 0.15 |
| Diastolic blood pressure (mmHg) | 74±10 | 75±10 | 75±10 | 75±11 | 74±11 | 73±11 | 0.02 |
| RAS inhibitors use (%) | 47 | 43 | 43 | 43 | 45 | 57 | <0.001 |
| Hypertension (%) | 67 | 64 | 61 | 61 | 65 | 71 | 0.001 |
| eGFR (ml/min/1.73 m2) | 77±25 | 77±22 | 78±21 | 76±21 | 72±21 | 67±24 | <0.001 |
The values are expressed as the mean ± SD or the percentage.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; OHA, oral hypoglycemic agent; RAS, renin-angiotensin system; eGFR, estimated glomerular filtration rate.
Obesity was defined as BMI ≥30 kg/m2. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or the current use of antihypertensive agents.
Figure 1The percentile plot of the urinary albumin-creatinine ratio (UACR) levels according to sleep duration in Japanese type 2 diabetic patients.
The bottom and top of the box are the 25th and 75th percentile, respectively, and the band in the box is the median. *p<0.05, **p<0.01 vs. sleep duration of 6.5–7.4 hours per day.
Figure 2Proportions of patients with albuminuria (A) or macroalbuminuria (B) according to sleep duration in Japanese type 2 diabetic patients.
Albuminuria was defined as urinary albumin-creatinine ratio (UACR) ≥30 mg/g, and macroalbuminuria was defined as UACR ≥300 mg/g. *p<0.05, **p<0.01 vs. sleep duration of 6.5–7.4 hours per day.
Adjusted partial regression coefficients (95% CIs) of log-transformed UACR according to sleep duration.
| Sleep duration (h) | P for quadratic trend(across categories) | P for quadratic trend (continuous) | ||||||
| < 4.5 | 4.5–5.4 | 5.5–6.4 | 6.5–7.4 | 7.5–8.4 | ≥ 8.5 | |||
| Age- and sex-adjusted | 0.38 | 0.18 | 0.01 | 0 | 0.13 | 0.49 | <0.001 | <0.001 |
| (0.13, 0.64) | (0.02, 0.34) | (−0.11, 0.14) | (referent) | (0.01, 0.26) | (0.32, 0.66) | |||
| Multivariate-adjusted | 0.33 | 0.17 | 0.03 | 0 | 0.09 | 0.38 | <0.001 | <0.001 |
| (0.08, 0.57) | (0.02, 0.32) | (−0.09, 0.14) | (referent) | (−0.03, 0.21) | (0.22, 0.54) | |||
| Multivariate-adjusted | 0.25 | 0.11 | 0.01 | 0 | 0.08 | 0.36 | <0.001 | <0.001 |
| + BMI | (0.001, 0.49) | (−0.04, 0.26) | (−0.10, 0.13) | (referent) | (−0.03, 0.20) | (0.20, 0.52) | ||
| Multivariate-adjusted | 0.25 | 0.14 | 0.02 | 0 | 0.08 | 0.33 | <0.001 | <0.001 |
| + HbA1c | (0.01, 0.49) | (−0.01, 0.29) | (−0.10, 0.13) | (referent) | (−0.04, 0.20) | (0.18, 0.49) | ||
| Multivariate-adjusted | 0.29 | 0.14 | 0.02 | 0 | 0.10 | 0.32 | <0.001 | <0.001 |
| + SBP and RASI use | (0.06, 0.52) | (0.001, 0.29) | (−0.09, 0.13) | (referent) | (−0.02, 0.21) | (0.16, 0.47) | ||
| Multivariate-adjusted | 0.31 | 0.17 | 0.03 | 0 | 0.09 | 0.38 | <0.001 | <0.001 |
| + depressive symptoms | (0.06, 0.56) | (0.02, 0.32) | (−0.09, 0.14) | (referent) | (−0.03, 0.21) | (0.22, 0.54) | ||
| Multivariate-adjusted+ BMI, HbA1c, | 0.21 | 0.11 | 0.01 | 0 | 0.08 | 0.28 | <0.001 | <0.001 |
| SBP, RASI use, and depressive symptoms | (−0.02, 0.44) | (−0.04, 0.25) | (−0.10, 0.12) | (referent) | (−0.03, 0.20) | (0.12, 0.43) | ||
The numbers in parentheses represent the 95% CIs.
Abbreviations: UACR, urinary albumin-creatinine ratio; BMI, body mass index; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; RASI, renin-angiotensin system inhibitor.
Multivariate adjustment was made for age, sex, duration of diabetes, current smoking habits, former smoking habits, current drinking habits, regular exercise habits, total energy intake, total protein intake, hypnotic use and estimated glomerular filtration rate.